© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 11, 906-908,
June 2, 1999
© 1999 Oxford University Press
NEWS |
Hepatitis C Vaccine Hampered by Viral Complexity, Many Technical Restraints
Singly and together hepatitis B and C viruses are the leading cause of cirrhosis of the liver and hepatocellular carcinoma, the most common form of primary liver cancer by far. But while a vaccine against the widespread hepatitis B virus became available as early as 1982, one against hepatitis C also bloodborne, equally commonplace, and frequently chronic has proven far more elusive.
And the prospects for an HCV vaccine are not immediate. Despite being distantly related to
the yellow fever virus for which there is a vaccine, says Robert Purcell, M.D., who heads viral hepatitis research at the National Institute of Allergy and Infectious
Diseases, "it [HCV] shares with the Human Immunodeficiency Virus an
extreme genetic heterogeneity, including hypervariable regions. Patients tend to harbor a mix of
genomes and
Scant Research
Treatment Barriers